Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating nephrotic syndrome

A technology for nephrotic syndrome and a composition is applied in the field of medicine and can solve the problems of ineffective calcineurin inhibitor and mycophenolate mofetil, many side effects of glucocorticoids, and large toxic and side effects of cyclophosphamide, etc.

Pending Publication Date: 2020-09-08
BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The purpose of the present invention is to solve the current clinical treatment of nephrotic syndrome, many side effects of glucocorticoids, cyclophosphamide toxic and side effects, calcineurin inhibitors and mycophenolate mofetil effect is not obvious and other problems

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating nephrotic syndrome
  • Pharmaceutical composition for treating nephrotic syndrome
  • Pharmaceutical composition for treating nephrotic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Embodiment 1 Application of the pharmaceutical composition of the present invention in the preparation of medicines for the treatment of nephrotic syndrome

[0061] The dose of prednisone is 0.5mg / kg / day, the maximum dose is 30mg / day.

[0062] The dose of cyclosporine is 100 mg / day, taken in two divided doses, and the dose is adjusted according to the blood concentration.

[0063] The dose of mycophenolate mofetil is 1g / day, taken in two divided doses.

Embodiment 2

[0064] Embodiment 2 Application of the pharmaceutical composition of the present invention in the preparation of medicines for the treatment of nephrotic syndrome

[0065] The initial dose of prednisone is 0.5mg / kg / day, the maximum dose is 30mg / day, and it is maintained for 8 weeks. Afterwards, the dose should be reduced by 5mg / day every 4 weeks, when reduced to 20mg / day, reduced by 2.5mg / day every 8 weeks, and maintained for 4-6 months when reduced to 5mg / day.

[0066] The initial dose of cyclosporine is 100 mg / day, taken in two divided doses. The dose is adjusted according to the blood concentration, the target range of blood cyclosporine trough concentration is 80-120ng / ml, and the maximum dose is 300mg / day. If the condition is completely relieved, after 2 weeks of maintenance, reduce the dose by 25mg / day every 8 weeks. Reduce to 50mg / day, maintain treatment with 50mg / day for 12 months, then reduce to 25mg / day, and maintain the total course of treatment up to 60 months. ...

Embodiment 3

[0067] The initial dose of mycophenolate mofetil is 1 g / day, taken in two divided doses. If the condition is completely relieved, after 2 weeks of maintenance treatment, gradually reduce the dose, reducing 0.25g / day every 8 weeks. When the dose is reduced to 0.5g / day, maintain treatment for 12 months and then reduce the dose, and maintain treatment with 0.25g / day for 12 months. If the condition is only partially remitted or not remitted, the target dose is maintained for 18 months, and then gradually reduced. Embodiment 3 Application of the pharmaceutical composition of the present invention in the preparation of medicines for the treatment of nephrotic syndrome

[0068] The dose of prednisone is 0.5mg / kg / day, the maximum dose is 30mg / day.

[0069] The dose of tacrolimus is 1 mg / day, taken in two divided doses, and the dose is adjusted according to the blood concentration.

[0070] The dose of mycophenolate mofetil is 1g / day, taken in two divided doses.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating nephrotic syndrome. The pharmaceutical composition comprises glucocorticoid, a calcineurin inhibitor, mycophenolic acid, or a pharmaceutically acceptable salt and prodrug of mycophenolic acid. The pharmaceutical composition not only can play a role in multiple links of immunosuppression in a process of treating nephrotic syndrome, especially idiopathic membranous nephropathy and achieve a better effect through synergism of drug effects, but also can obviously reduce the dosage of each drug and reduce respective adverse reactionsand toxic and side effects.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition for treating nephrotic syndrome. Background technique [0002] Nephrotic syndrome is a disease that seriously endangers human health. The main clinical manifestations include massive proteinuria, hypoalbuminemia, edema, hypertension, and even renal insufficiency. Membranous nephropathy is one of the most common pathological types of nephrotic syndrome, a group of diseases characterized by the deposition of immune complexes under the epithelial cells of the glomerular basement membrane and diffuse thickening of the basement membrane. Membranous nephropathy is divided into idiopathic membranous nephropathy and secondary membranous nephropathy, among which idiopathic membranous nephropathy accounts for about 80% of membranous nephropathy patients. [0003] The exact pathogenesis of idiopathic membranous nephropathy is unclear, but it may be caused by a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/365A61K31/573A61K38/13A61K31/436A61P13/12A61P13/00A61P31/00
CPCA61K31/365A61K31/436A61K31/573A61K38/13A61K45/06A61P13/00A61P13/12A61P31/00A61K2300/00
Inventor 刁宗礼刘文虎郭王姜群王刚黄红东
Owner BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com